

## PROGRAMME AND PRICES 2024

# Prices are excluding VAT

<b>ANNUAL SUBSCRIPTION</b>		
<b>The annual subscription fee is mandatory for each participant.</b>		
DESCRIPTION	PRICE (EURO) #	PRODUCT CODE
Annual Subscription Fee: Result submission via ECAT website / survey report via website as pdf	147.00	101

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>MAIN PROGRAMME</b>							
<b>Thrombophilia - I:</b> Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free)	4	2024-M1	2024-M2	2024-M3	2024-M4	412.50	402
<b>Thrombophilia - II</b> APC Resistance	4	2024-M1	2024-M2	2024-M3	2024-M4	167.00	417
<b>Coagulation Factor - I</b> Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C	4	2024-M1	2024-M2	2024-M3	2024-M4	208.50	406
<b>Coagulation Factor - II</b> Factor II:C, V:C, VII:C and X:C	4	2024-M1	2024-M2	2024-M3	2024-M4	208.50	407
<b>Von Willebrand Factor parameters</b> (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII)	4	2024-M1	2024-M2	2024-M3	2024-M4	313.50	408
<b>ADAMTS13 - I</b> (activity and antigen)	4	2024-M1	2024-M2	2024-M3	2024-M4	219.50	409
<b>ADAMTS13 - II</b> (antibodies)	2		2024-M2		2024-M4	143.75	410
<b>ADAMTS13 - III</b> (functional inhibitor)	1		2024-M2			104.50	419
<b>Factor XIII</b> (activity and antigen)	4	2024-M1	2024-M2	2024-M3	2024-M4	156.25	411
<b>Fibrinolysis - I</b> Plasminogen, Antiplasmin	4	2024-M1	2024-M2	2024-M3	2024-M4	151.50	412
<b>Fibrinolysis - II</b> t-PA, PAI-1	4	2024-M1	2024-M2	2024-M3	2024-M4	151.50	413
<b>LUPUS PROGRAMME</b>							
<b>Lupus Anticoagulant / Antiphospholipid Antibodies</b>	4	2024-L1	2024-L2	2024-L3	2024-L4	198.50	404
<b>D-DIMER PROGRAMME</b>							
<b>D-Dimer</b>	4	2024-D1	2024-D2	2024-D3	2024-D4	151.50	405

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES								PRICE (EURO) #	PRODUCT CODE
<b>SCREEN PROGRAMME</b>											
Screen - I: APTT, PT/INR and Fibrinogen	8	2024-S1	2024-S2	2024-S3	2024-S4	2024-S5	2024-S6	2024-S7	2024-S8	264.00	501
Screen - II: Thrombin Time, Reptilase Time	8	2024-S1	2024-S2	2024-S3	2024-S4	2024-S5	2024-S6	2024-S7	2024-S8	264.00	502

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>APTT / PT MIXING TEST PROGRAMME</b>							
APTT / PT Mixing Test	4	2024-Mix1	2024-Mix2	2024-Mix3	2024-Mix4	220.00	503

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>HAEMOPHILIA PROGRAMME</b>							
Haemophilia Factor VIII (clot and chromogenic activity) Factor IX (clot and chromogenic activity)	4	2024-H1	2024-H2	2024-H3	2024-H4	266.50	418
Factor VIII inhibitor	2		2024-H2		2024-H4	206.50	202
Factor IX Inhibitor	2	2024-H1		2024-H3		206.50	201
Emicizumab	2		2024-H2		2024-H4	206.50	223
Kovaltry (Bayer)	2	2024-H1		2024-H3		205.00	228
Jivi (Bayer)	2	2024-H1		2024-H3		205.00	229
Esperoct (Novo Nordisk)	2		2024-H2		2024-H4	205.00	230
NovoEight (Novo Nordisk)	2		2024-H2		2024-H4	205.00	231
Refixia (Novo Nordisk)	2		2024-H2		2024-H4	205.00	232

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>Fibrin(ogen) Degradation Products</b>							
FDP	4	2024-F1	2024-F2	2024-F3	2024-F4	151.50	420

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>ANTICOAGULATION PROGRAMME</b>							
Unfractionated Heparin Monitoring (anti-Xa)	4	2024-A1	2024-A2	2024-A3	2024-A4	136.00	414
Low-Molecular Weight Heparin Monitoring (anti-Xa)	4	2024-A1	2024-A2	2024-A3	2024-A4	136.00	415
Orgaran (anti-Xa)	2		2024-A2		2024-A4	69.50	205
Fondaparinux (anti-Xa)	2		2024-A2		2024-A4	69.50	206
Rivaroxaban (anti-Xa)	2		2024-A2		2024-A4	69.50	207
Apixaban (anti-Xa)	2		2024-A2		2024-A4	69.50	208
Edoxaban (anti-Xa)	2		2024-A2		2024-A4	69.50	221
Argatroban (anti-IIa/dTT)	2		2024-A2		2024-A4	69.50	209
Dabigatran (anti-IIa/dTT)	2		2024-A2		2024-A4	69.50	210

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>THROMBOELASTOGRAPHY PROGRAMME</b>							
<b>ROTEM delta</b> <input type="checkbox"/> 1 instrument / 1 set of samples ROTEM <input type="checkbox"/> 2 instruments / 2 sets of samples ROTEM <input type="checkbox"/> 3 instruments / 3 sets of samples ROTEM	4	2024-T1	2024-T2	2024-T3	2024-T4	347.50	212
						590.75	213
						834.00	214
<b>ROTEM sigma</b> <input type="checkbox"/> 1 instrument / 1 set of samples ROTEM <input type="checkbox"/> 2 instruments / 2 sets of samples ROTEM <input type="checkbox"/> 3 instruments / 3 sets of samples ROTEM	4	2024-T1	2024-T2	2024-T3	2024-T4	347.50	215
						590.75	216
						834.00	217
<b>TEG</b> <input type="checkbox"/> 1 instrument / 1 set of samples TEG <input type="checkbox"/> 2 instruments / 2 sets of samples TEG <input type="checkbox"/> 3 instruments / 3 sets of samples TEG	4	2024-T1	2024-T2	2024-T3	2024-T4	347.50	218
						590.75	219
						834.00	220
<b>CLOT-PRO</b> <input type="checkbox"/> 1 instrument / 1 set of samples CLOT-PRO <input type="checkbox"/> 2 instruments / 2 sets of samples CLOT-PRO <input type="checkbox"/> 3 instruments / 3 sets of samples CLOT-PPRO	4	2024-T1	2024-T2	2024-T3	2024-T4	347.50	224
						590.75	225
						834.00	226
<b>THROMBIN GENERATION PROGRAMME</b>							
Thrombin Generation Test	2	2024-TG1		2024-TG3		157.50	203
<b>PFA PROGRAMME</b>							
PFA-100/200	2	2024-P1		2024-P3		492.50	222
<b>HIT PROGRAMME</b>							
HIT - I (immunological testing)	2	2024-HIT1		2024-HIT3		235.00	204

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>ACT PROGRAMME</b> <b>Note: samples will be distributed separately from other surveys. For details see Survey Schedule 2024</b>							
Activated Clotting Time	2		2024-ACT1		2024-ACT2	132.50	504

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
<b>POCT INR QC PROGRAMME</b> <b>No annual subscription fee applicable if only participating in the POCT INR QC Programme.</b>							
POCT INR QC Programme for CoaguChek INR Monitors (any type)	4	2024-Q1	2024-Q2	2024-Q3	2024-Q4	473.00	301
* Annual shipping costs for countries outside Europe: on request.							

DESCRIPTION	ORGANISED BY	NUMBER OF SURVEYS	SURVEY PERIOD(S)	PRICE (EURO) #	PRODUCT CODE
<b>OTHER SURVEYS</b>					
Post Analytical Platelet Function EQA (electronic surveys)	Nascola, USA	2	Spring, Autumn	250.00	701
Platelet Dense Granule exercise (electronic surveys)	Nascola, USA	2	Spring, Autumn	250.00	704
Whole Blood Impedance Platelet Aggregation (electronic surveys)	Nascola, USA	2	Spring, Autumn	220.00	707
Case study on bleeding disorders (will be distributed together with survey 2024-3)	ECAT	1	2024-3	115.00	703
Case study on anticoagulation bridging (will be distributed together with survey 2024-2)	ECAT	1	2024-2	115.00	706
Pre- and post-analytical electronic survey in haemostasis	ECAT	1	Autumn	80.00	705

<b>HOMOCYSTEINE (In co-operation with the DEKS, Denmark)</b>							
DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
Homocysteine	4	2024-01	2024-02	2024-03	2024-04	185.00	1001

MOLECULAR BIOLOGY (In co-operation with the SPMD, Germany)						
SURVEY	DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES		PRICE (EURO) #	PRODUCT CODE
<b>MOLECULAR GENETICS MG1</b>						
MG1 Set A	For details: see below	2	MG1 1/24	MG1 2/24	**	601
MG1 Set B	For details: see below	2	MG1 1/24	MG1 2/24	**	602
MG1 Set C	For details: see below	2	MG1 1/24	MG1 2/24	**	603
MG1 Set D	For details: see below	2	MG1 1/24	MG1 2/24	**	604
MG1 Set E	For details: see below	2	MG1 1/24	MG1 2/24	**	605
MG1 Set F	For details: see below	2	MG1 1/24	MG1 2/24	**	606
<b>MOLECULAR GENETICS MG2</b>						
MG2 Set A	For details: see below	2	MG2 1/24	MG2 2/24	**	801
MG2 Set B	For details: see below	2	MG2 1/24	MG2 2/24	**	802
MG2 Set C	For details: see below	2	MG2 1/24	MG2 2/24	**	803
MG2 Set D	For details: see below	2	MG2 1/24	MG2 2/24	**	804
MG2 Set E	For details: see below	2	MG2 1/24	MG2 2/24	**	805
MG2 Set F	For details: see below	2	MG2 1/24	MG2 2/24	**	806
<b>PRICES MG1 or MG2</b>						
** <b>MG1 or MG2:</b> One set :      € 108.00      Three sets:      € 324.00      Five sets:      € 540.00 Two sets:      € 216.00      Four sets:      € 432.00      Six sets:      € 648.00						
<b>DNA SEQUENCING SQ</b>						
Sequencing and interpretation		2	SQ 1/24	SQ 2/24	264.00	901
<b>DNA ISOLATION DI</b>						
DNA Isolation and genotyping (For details: see below)		2	DI 1/24	DI 2/24	136.00	902
Extra costs for shipment of Molecular Biology surveys		Per registration for one or more of the Molecular Biology surveys an annual fee of € 65.50 will be charged.				

### Details MG1

- Set A:**
- FV-Leiden (F5, NM\_000130.5:c.1601G>A, rs6025)
  - FII g20210a (F2, NM\_000506.5:c.\*97G>A, rs1799963)
  - Methylenetetrahydrofolate reductase (MTHFR)
  - MTHFR C677T (MTHFR, NM\_005957.5:c.665C>T, rs1801133)
  - MTHFR A1298C (MTHFR, NM\_005957.5:c.1286A>C, rs1801131)
  - PAI-I 4G5G (SERPINE1, NM\_000602.5:c.-820G[(4\_5)], rs1799762)

- Set B:**
- FXIII V34L (F13A1, NM\_000129.4:c.103G>T, rs5985)
  - GPIIIa (ITGB3, NM\_000212.3:c.176T>C, rs5918)
  - beta-Fibrinogen g-455a (FGB, NM\_005141.4:c.-463G>A, rs1800790)
  - Vitamin K epoxide reductase complex subunit 1 (VKORC1)
  - VKORC1 G-1639 (VKORC1, NM\_024006.6:c.-1639G>A, rs9923231)
  - VKORC1 C1173T (VKORC1, NM\_024006.6:c.174-136C>T, rs9934438)
  - FXII c46t (F12, NM\_000505.4:c.-4T>C rs1801020)
  - FV-H1299R (F5, NM\_000130.5:c.3980A>G, rs1800595)

- Set C:**
- Alpha-1-Antitrypsin, (serpin family A member1)
  - AAT-PI\*S (SERPINA1, NM\_000295.5:c.863A>T, rs17580)
  - AAT-PI\*Z (SERPINA1, NM\_000295.5:c.1096G>A, rs28929474)
  - AAT- (Alpha-1-Antitrypsin-Genotyping)
  - Apolipoprotein E (APOE)
  - ApoE2 (APOE, NM\_000041.4:c.526C>T, rs7412)
  - ApoE4 (APOE, NM\_000041.4:c.388T>C, rs429358)
  - ApoE (Apolipoprotein E – Genotyping)
  - ApoB100 (APOB, NM\_000384.3:c.10580G>A, rs5742904)
  - ACE I/D (ACE, NM\_000789.3:c.2306-117\_2306-116insAF118569.1:g.14094\_14382, rs1799752)
  - CETP B1/B2 (CETP, NM\_000078.3:c.118+279G>A, rs708272)

- Set D:**
- Aldolase, fructose-bisphosphate B (ALDOB)
  - AldoB 149 (ALDOB, NM\_000035.4:c.448G>C, rs1800546)
  - AldoB 174 (ALDOB, NM\_000035.4:c.524C>A, rs76917243)
  - AldoB 334 (ALDOB, NM\_000035.4:c.1005C>G, rs78340951)
  - Hereditary Hemochromatosis (HFE)
  - HFE H63D (HFE, NM\_000410.4:c.187C>G, rs1799945)
  - HFE S65C (HFE, NM\_000410.4:c.193A>T, rs1800730)
  - HFE C282Y (HFE, NM\_000410.4:c.845G>A, rs1800562)
  - LCT c-13910t (LCT, NM\_005915.6:c.1917+326C>T, rs4988235)
  - Nucleotide binding oligomerization domain containing 2 (NOD2)
  - NOD R702W (NOD2, NM\_001370466.1:c.2023C>T, rs2066844)
  - NOD G908R (NOD2, NM\_001370466.1:c.2641G>C, rs2066845)
  - NOD L1007finsC (NOD2, NM\_001370466.1:c.2938dup, rs2066847)

- Set E:**
- ATP7B-C3207A (ATP7B, NM\_000053.4:c.3207C>A, rs76151636)
  - FSAP Marburg-I (HABP2, NM\_004132.5:c.1601G>A, rs7080536)
  - ITGA2 GplIIa C807T (ITGA2, NM\_002203.4:c.759C>T, rs1126643)
  - Col1A1 SP1 (Col1A1, NM\_000088.4:c.104-441G>T, rs1800012)
  - Vitamin D receptor (VDR)
  - VDR BsmI (VDR, NM\_000376.3:c.1024+283G>A, rs1544410)
  - VDR ApaI (VDR, NM\_000376.3:c.1025-49G>T, rs7975232)
  - VDR TaqI (VDR, NM\_000376.3:c.1056T>C, rs731236)

- Set F:**
- Faktor VII (R353Q) (F7, NM\_019616.4:c.1172G>A, rs6046)
  - AT3 Cambridge Typ I/II (SERPINC1, NM\_000488.4:c.1246G>C>T, rs121909548)
  - CYP3A5\*3 (CYP3A5, NM\_000777.5:c.219-237A>G, rs776746)

## **Details MG2**

- Set A:**
- Thiopurine S-methyltransferase (TPMT)
  - TPMT\*2 (TPMT, NM\_000367.5:c.238G>C, rs1800462)
  - TPMT\*3B (TPMT, NM\_000367.5:c.460G>A, rs1800460)
  - TPMT\*3C (TPMT, NM\_000367.5:c.719A>G, rs1142345)
  - Thiopurine S-methyltransferase (TPMT – Genotyping)
  - CYP2C8\*3 (CYP2C8, NM\_000770.3:c.1196A>G, rs10509681)
  - Cytochrom P450 2C9 (CYP2C9)
  - CYP2C9\*2 (CYP2C9, NM\_000771.4:c.430C>T, rs1799853)
  - CYP2C9\*3 (CYP2C9, NM\_000771.4:c.1075A>C, rs1057910)
  - CYP2C9 (2C9 – Genotyping)
  - UGT1A1\*28 (UGT1A1, NM\_000463.3:c.-41\_-40dupTA, rs3064744)
  - Dihydropyrimidine dehydrogenase (DPYD)
  - DPYD\*2A (DPYD, NM\_000110.4:c.1905+1G>A, rs3918290)
  - DPYD\*13 (DPYD, NM\_000110.4:c.1679T>G, rs55886062)
  - DPYD p.D949V (DPYD, NM\_000110.4:c.2846A>T, rs67376798)

- DPYD c.1129-5923C>G (DPYD, NM\_000110.4:c.1129-5923C>G, rs75017182)
- DPYD c.1236G>A (DPYD, NM\_000110.4:c.1236G>A, rs56038477)
- DPYD HapB3 (DPYD, NM\_000110.4:c.1129-5923C>G, rs75017182, NM\_000110.4:c.1236G>A, rs56038477)
- DPD activity score acc. to CPIC
- DPD activity score acc. to DGHO
- BCHE A (D70G) (BCHE, NM\_000055.4:c.293A>G, rs1799807)
- BCHE K (A567T) (BCHE, NM\_000055.4:c.1699G>A, rs1803274)

- Set B:** KRAS proto-oncogene, GTPase (KRAS)
- KRAS p.G12/p.G13 (KRAS, NP\_004976.2:p.G12/G13)
  - KRAS p.G12 (KRAS, NM\_004985.5:c.34G>T>C>A, rs121913530)
  - KRAS p.G12 (KRAS, NM\_004985.5:c.35G>T>C>A, rs121913529)
  - KRAS p.G13 (KRAS, NM\_004985.5:c.37G>T>C>A, rs121913535)
  - KRAS p.G13 (KRAS, NM\_004985.5:c.38G>T>C>A, rs112445441)
  - KRAS p.G12 (KRAS, NP\_004976.2:p.G12)
  - KRAS p.G12 (KRAS, NM\_004985.5:c.34G>T>C>A, rs121913530)
  - KRAS p.G12 (KRAS, NM\_004985.5:c.35G>T>C>A, rs121913529)
  - KRAS p.G13 (KRAS, NP\_004976.2:p.G13)
  - KRAS p.G13 (KRAS, NM\_004985.5:c.37G>T>C>A, rs121913535)
  - KRAS p.G13 (KRAS, NM\_004985.5:c.38G>T>C>A, rs112445441)
  - KRAS p.Q61 (KRAS, NP\_004976.2:p.Q61)
  - KRAS p.Q61 (KRAS, NM\_004985.5:c.181C>G>A, rs121913238)
  - KRAS p.Q61 (KRAS, NM\_004985.5:c.182A>T>G>C, rs121913240)
  - KRAS p.Q61 (KRAS, NM\_004985.5:c.183A>T>C, rs17851045)
  - BRAF p.V600 (BRAF, NP\_004324.2:p.V600E/K, rs113488022, rs121913227)
  - NM\_004333.6:c.1799T>A, rs113488022
  - NM\_004333.6:c.1798\_1799delinsAA, rs121913227
  - cKIT p.D816V (KIT, NM\_000222.3:c.2447A>T, rs121913507)
  - NRAS (NRAS, NP\_002515.1:p.Q61)
  - NRAS (NRAS, NM\_002524.5:c.181C>T>G>A, rs121913254)
  - NRAS (NRAS, NM\_002524.5:c.182A>T>G>C, rs11554290)
  - NRAS (NRAS, NM\_002524.5:c.183A>T>C, rs121913255)

- Set C:**
- HLA-B\*27 (HLA-B, NM\_005514.8)
  - TNF alpha 238 (TNF, NM\_000594.3:c.-418G>A, rs361525)
  - TNF alpha 308 (TNF, NM\_000594.3:c.-488G>A, rs1800629)

- Set D:** Cytochrome P450 2D6 (CYP2D6)
- CYP2D6\*2-296 (CYP2D6\*2, NM\_000106.6:c.886C>T, rs16947)
  - CYP2D6\*2-486 (CYP2D6\*2, NM\_000106.6:c.1457G>C, rs1135840)
  - CYP2D6\*3 (CYP2D6\*3, NM\_000106.6:c.775del, rs35742686)
  - CYP2D6\*4 (CYP2D6\*4, NM\_000106.6:c.506-1G>A, rs3892097)
  - CYP2D6\*6 (CYP2D6\*6, NM\_000106.6:c.454del, rs5030655)
  - CYP2D6\*7 (CYP2D6\*7, NM\_000106.6:c.971A>C, rs5030867)
  - CYP2D6\*8 (CYP2D6\*8, NM\_000106.6:c.505G>T, rs5030865)
  - CYP2D6\*9 (CYP2D6\*9, NM\_000106.6:c.841\_843del, rs5030656)
  - CYP2D6\*10 (CYP2D6\*10, NM\_000106.6:c.100C>T, rs1065852)
  - CYP2D6\*17 (CYP2D6\*17, NM\_000106.6:c.320C>T, rs28371706)
  - CYP2D6\*35 (CYP2D6\*35, NM\_000106.6:c.31G>A, rs769258)
  - CYP2D6\*41 (CYP2D6\*41, NM\_000106.6:c.985+39G>A, rs28371725)
  - CYP2D6\*5 (CYP2D6, Deletion)
  - CYP2D6\*xN (CYP2D6, Duplication/Amplification)
  - Cytochrome P450 2C19 (CYP2C19)
  - CYP2C19\*2 (CYP2C19, NM\_000769.4:c.681G>A, rs4244285)
  - CYP2C19\*3 (CYP2C19, NM\_000769.4:c.636G>A, rs4986893)
  - CYP2C19\*17 (CYP2C19, NM\_000769.4:c.-806C>T, rs12248560)
  - CYP2C19 Genotyping

- Set E:**
- HLA B\*57:01 (HLA-B, NM\_005514.8)
  - Cytochrome P450 2B6 (CYP2B6)
  - CYP2B6\*4 (CYP2B6, NM\_000767.5:c.785A>G, rs2279343)
  - CYP2B6\*9 (CYP2B6, NM\_000767.5:c.516G>T, rs3745274)
  - CYP2B6\*6 (CYP2B6, NM\_000767.5:c.785A>G, rs2279343 + NM\_000767.5:c.516G>T, rs3745274)
  - ABCB1 c.3435T>C (ABCB1, NM\_001348946.2:c.3435T>C, rs1045642)
  - CCR5-del32bp (CCR5, NM\_001394783.1:c.554\_585del, rs333)

- Set F:**
- IL28B (C/T Polymorphism) (IFNL4, NM\_001276254.2:c.151-152G>A, rs12979860)
  - IL6 G(-174)C (IL6, NM\_000600.4:c.-237C>G, rs1800795)
  - CYP3A4\*22 (CYP3A4, NM\_017460.6:c.522-191C>T, rs35599367)

### Details DNA Isolation and genotyping

- FV-Leiden (F5, NM\_000130.5:c.1601G>A, rs6025)
- FV-H1299R (F5, NM\_000130.5:c.3980A>G, rs1800595)
- FV-Cambridge (F5, NM\_000130.5:c.1001G>C, rs118203906)
- FV-Hong-Kong (F5, NM\_000130.5:c.1000A>G, rs118203905)
- FII g20210a (F2, NM\_000506.5:c.\*97G>A, rs1799963)
- Methylene tetrahydrofolate reductase (MTHFR)
- MTHFR C677T (MTHFR, NM\_005957.5:c.665C>T, rs1801133)
- MTHFR A1298C (MTHFR, NM\_005957.5:c.1286A>C, rs1801131)
- Hereditary Hemochromatosis (HFE)
- HFE H63D (HFE, NM\_000410.4:c.187C>G, rs1799945)
- HFE S65C (HFE, NM\_000410.4:c.193A>T, rs1800730)
- HFE C282Y (HFE, NM\_000410.4:c.845G>A, rs1800562)

## DETAILED SAMPLE INFORMATION

Description	Survey Code	Number of different samples per survey	Number of vials per sample code	Component
<b>Thrombophilia - I:</b> Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free)	M	2	2	Plasma, lyophilised
<b>Thrombophilia - II</b> APC Resistance	M	2	1	Plasma, lyophilised
<b>Coagulation Factor - I</b> Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C	M	2	2	Plasma, lyophilised
<b>Coagulation Factor - II</b> Factor II:C, V:C, VII:C and X:C	M	2	2	Plasma, lyophilised
<b>Von Willebrand Factor parameters</b> (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII)	M	2	2	Plasma, lyophilised
<b>ADAMTS13 - I</b> (activity and antigen)	M	2	1	Plasma, lyophilised
<b>ADAMTS13 - II</b> (antibodies)	M	2	1	Plasma, lyophilised
<b>ADAMTS13 - III</b> (functional inhibitor)	M	2	1	Plasma, lyophilised
<b>Factor XIII</b> (activity and antigen)	M	2	1	Plasma, lyophilised
<b>Fibrinolysis - I</b> Plasminogen, Antiplasmin	M	2	1	Plasma, lyophilised
<b>Fibrinolysis - II</b> t-PA, PAI-1	M	2	1	Plasma, lyophilised
<b>Haemophilia</b> Factor VIII / Factor IX (clot and chromogenic activity)	H	2	1	Plasma, lyophilised
<b>Factor VIII inhibitor</b>	H	2	1	Plasma, lyophilised
<b>Factor IX Inhibitor</b>	H	2	1	Plasma, lyophilised



**DETAILED SAMPLE INFORMATION**

Description	Survey Code	Number of different samples per survey	Number of vials per sample code	Component
Emicizumab	H	2	1	Plasma, lyophilised
Kovaltry	H	2	1	Plasma, lyophilised
Jivi	H	2	1	Plasma, lyophilised
Esperoct	H	2	1	Plasma, lyophilised
NovoEight	H	2	1	Plasma, lyophilised
Refixia	H	2	1	Plasma, lyophilised
<b>Lupus Anticoagulant / Antiphospholipid Antibodies</b>	L	1	2	Plasma, lyophilised
<b>Unfractionated Heparin Monitoring</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Low-Molecular Weight Heparin Monitoring</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Orgaran</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Fondaparinux</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Rivaroxaban</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Apixaban</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Edoxaban</b> (anti-Xa)	A	2	1	Plasma, lyophilised
<b>Argatroban</b> (anti-IIa/dTT)	A	2	1	Plasma, lyophilised
<b>Dabigatran</b> (anti-IIa/dTT)	A	2	1	Plasma, lyophilised
<b>D-Dimer</b>	D	2	1	Plasma, lyophilised
<b>Screen - I</b> APTT, PT/INR and Fibrinogen	S	2	1	Plasma, lyophilised
<b>Screen - II</b> Thrombin Time, Reptilase Time	S	2	1	Plasma, lyophilised
<b>Thrombin Generation Test</b>	TG	3	1	Plasma, lyophilised
<b>PFA-100/200</b>	P	2	2	tubes ± additives
<b>ROTEM delta</b> (samples per set)	T	2	1	Plasma, lyophilised
<b>ROTEM sigma</b> (samples per set)	T	2	1	Plasma, lyophilised
<b>TEG</b> (samples per set)	T	2	1	Plasma, lyophilised
<b>CLOT-PRO</b> (samples per set)	T	2	1	Plasma, lyophilised
<b>HIT - I</b> (immunological testing)	HIT	2	1	Plasma or serum, lyophilised
<b>POCT INR QC Programme</b>	Q	4	1	Plasma, lyophilised
<b>APTT / PT Mixing Test Programme</b>	MIX	2	1	Plasma, lyophilised
<b>Activated Clotting Time</b>	ACT	2	1	Artificial whole blood
<b>FDP</b>	F	2	1	Plasma, lyophilised
<b>Homocysteine</b>		2	1	Plasma, liquid
<b>Post Analytical Platelet Function EQA (electronic survey)</b>		-	-	-
<b>Platelet Dense Granule exercise (electronic survey)</b>		-	-	-
<b>Whole Blood Impedance Platelet Aggregation (electronic survey)</b>		-	-	-
<b>Case study on bleeding disorders</b>		1	1 or 2	Plasma, lyophilised
<b>Case study on anticoagulation bridging</b>		1	1	Plasma, lyophilised
<b>Pre- and post-analytical electronic surveys in haemostasis</b>		-	-	-
<b>Molecular Genetics MG1</b>		2	1	DNA preparation, lyophilised
<b>Molecular Genetics MG2</b>		2	1	DNA preparation, lyophilised
<b>DNA Sequencing</b>		5	1	DNA preparation, lyophilised
<b>DNA Isolation</b>		2	1	Full blood, K-EDTA

### LIST OF PARAMETERS

Parameter	Module	Survey Code
Activated Clotting Time	Activated Clotting Time	ACT
ADAMTS-13 activity	ADAMTS13 - I	M
ADAMTS-13 antigen	ADAMTS13 - I	M
ADAMTS-13 antibodies	ADAMTS13 - II	M
ADAMTS-13 functional antibodies	ADAMTS13 - III	M
Anticardiolipin antibodies (IgG, IgM)	Lupus Anticoagulant / Antiphospholipid Antibodies	L
Antithrombin activity	Thrombophilia - I	M
Antithrombin antigen	Thrombophilia - I	M
APC Resistance	Thrombophilia - II	M
Apixaban (anti-Xa)	Apixaban	A
APTT (clotting time / ratio)	Screen – I	S
APTT Mixing Test	APTT / PT Mixing Test	Mix
Argatroban (anti-IIa / dTT)	Argatroban	A
CLOT-PRO	CLOT-PRO	T
Dabigatran (anti-IIa / dTT)	Dabigatran	A
D-Dimer	D-Dimer	D
Edoxaban (anti-Xa)	Edoxaban	A
Emicizumab	Emicizumab	H
Esperoct	Haemophilia	H
Factor II:C	Coagulation Factor - II	M
Factor V:C	Coagulation Factor - II	M
Factor VII:C	Coagulation Factor - II	M
Factor VIII (clot and chromogenic)	Coagulation Factor - I / Haemophilia	M / H
Factor VIII Inhibitor	Factor VIII Inhibitor	H
Factor IX (clot and chromogenic)	Coagulation Factor - I / Haemophilia	M / H
Factor IX Inhibitor	Factor IX Inhibitor	H
Factor X:C	Coagulation Factor - II	M
Factor XI:C	Coagulation Factor - I	M
Factor XII:C	Coagulation Factor - I	M
Factor XIII activity	Factor XIII	M
Factor XIII antigen	Factor XIII	M
Fibrinogen (Clauss)	Screen – I	S
Fibrinogen (Derived)	Screen – I	S
Fibrinogen Degradation Products	FDP	F
Fondaparinux (anti-Xa)	Fondaparinux	A
β2-Glycoprotein I antibodies (IgG, IgM)	Lupus Anticoagulant / Antiphospholipid Antibodies	L
HIT (immunological testing)	HIT – I	HIT
Homocysteine	Homocysteine	-
INR	Screen – I	S
INR POCT	POCT INR QC Programme	Q
Jivi	Haemophilia	H

**LIST OF PARAMETERS**

Parameter	Module	Survey Code
Kovaltry	Haemophilia	H
Low-Molecular Heparin (anti-Xa)	Low-Molecular Heparin Monitoring	A
Lupus Anticoagulant	Lupus Anticoagulant / Antiphospholipid Antibodies	L
NovoEight	Haemophilia	H
Orgaran (anti-Xa)	Orgaran	A
PAI-1 activity	Fibrinolysis - II	M
PAI-I antigen	Fibrinolysis - II	M
PFA-100/200	PFA-100/200	P
Plasminogen activity	Fibrinolysis - I	M
Plasmin Inhibitor (antiplasmin) activity	Fibrinolysis - I	M
Protein C activity (chromogenic / clotting)	Thrombophilia - I	M
Protein C antigen	Thrombophilia - I	M
Protein S activity	Thrombophilia - I	M
Protein S antigen (total and free)	Thrombophilia - I	M
PT (clotting time, percentage)	Screen - I	S
PT Mixing Test	APTT / PT Mixing Test	Mix
Refixia	Haemophilia	H
Reptilase Time (clotting time / ratio)	Screen - II	S
Rivaroxaban (anti-Xa)	Rivaroxaban	A
ROTEM delta	ROTEM delta	T
ROTEM sigma	ROTEM sigma	T
TEG	TEG	T
Thrombin Generation Test	Thrombin Generation Test	TG
Thrombin Time (clotting time / ratio)	Screen - II	S
t-PA antigen	Fibrinolysis - II	M
Unfractionated Heparin (anti-Xa)	Unfractionated Heparin Monitoring	A
Von Willebrand Factor antigen	Von Willebrand Factor Parameters	M
Von Willebrand Factor ristocetin cofactor activity	Von Willebrand Factor Parameters	M
Von Willebrand Factor activity	Von Willebrand Factor Parameters	M
Von Willebrand Factor collagen binding	Von Willebrand Factor Parameters	M
Von Willebrand Factor multimers	Von Willebrand Factor Parameters	M
Von Willebrand Factor / Factor VIII	Von Willebrand Factor Parameters	M